Simufilam success already priced in to Cassava, and CONMED a buy in today's analyst action

seekingalpha2021-07-16

Positive simufilam data may already be priced into Cassava With the Alzheimer's Association International Conference less than two weeks away, Cantor Fitzgerald is downgrading shares of Alzheimer's ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
7